Definitive Contract 75N93021C00039
Award Date
8/1/21
Potential Completion Date
7/31/23
Potential Value
$570K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Molecular Express, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
CRYSTAL CITY, CA 90220, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $3,599,784 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Molecular Express, Inc., a minority-owned, self-certified small disadvantaged business. The contract is for the development of a Vesivax co-adjuvant formulation of 2E151, with a completion date of September 29, 2028. Molecular Express, Inc. specializes in innovative drug formulations, therapeutics, and vaccine technologies, particularly focused on infectious diseases...
This contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Molecular Express, Inc., focuses on the development of the company's Vesivax TLR7 Formula, a therapeutic vaccine candidate targeting infectious diseases. The $2,999,352.00 Firm Fixed Price contract, which does not have a set-aside designation, runs through August 31, 2027. Molecular Express is a minority-owned, small disadvantaged business that has previously secured numerous SBIR contracts and...
This is a $1,999,866.00 Firm Fixed Price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Molecular Express, Inc. for the design and engineering of Vesivax HIV immunogen formulations. The contract is a Total Small Business set-aside as part of the Small Business Innovation Research (SBIR) Program Phase II. Molecular Express is a minority-owned, self-certified small disadvantaged business...
This award is for a Small Business Innovation Research (SBIR) contract with the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID), valued at $213,800. The contract was awarded to Molecular Express, Inc., a minority-owned small business focused on developing biomedical research and treatments for infectious diseases.
The contract was awarded under SBIR Topic 061, "Mucosal Stimulatory Vesivax Vaccines Against Enteric Infections," with a...
Molecular Express Inc. was awarded a $2.3 million definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to evaluate different co-delivery methods of a model HIV antigen using the Vesivax liposomal platform. This contract was awarded under a Small Business Innovation Research solicitation issued jointly by NIH and the Centers for Disease Control and Prevention seeking proposals aligned with agency missions through innovative solutions...
This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,993, was awarded to Molecular Express Inc. to develop a Vesivax platform-based liposomal formulation that will efficiently display the HIV immunogen. The solicitation sought proposals to conduct research and development in support of NIH and CDC agency missions, including alternatives to cell culture materials, cancer immunotherapy manufacturing, and...
The prime contractor Molecular Express Inc. was awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract by the National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, the contractor will engineer novel HIV GP41 ectodomain antigens for incorporation into VESIVAX immunogenic formulations, in response to a solicitation seeking proposals aligned with NIH and CDC public health missions. This total small...
The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $43,616 firm fixed price purchase order to Life Technologies Corporation. Under this contract, Life Technologies will provide 32 units of EXPI 293 Expression Media to the agency in five shipments for use in its research programs. Performance will occur in Carlsbad, California and last through the end of calendar year 2024. No set aside designation or...
The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $1.5 million firm fixed-price purchase order to Expression Systems LLC of Davis, California. The contract is for the manufacture of non-GMP material for animal testing in support of COVID-19 response efforts. Work will be performed in Davis, California through September 30, 2020. No subcontractors or additional context were provided regarding...
The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $16,345.50 purchase order to Biointron Biological USA Inc. for antibody expression services. As a firm fixed price contract, Biointron will provide the requested antibody expression services to NIH/NIAID at Metuchen, New Jersey from September 19, 2023 through December 29, 2023. No subcontractors or set aside designations were indicated. NIAID conducts...